Researchers found that a new treatment called BXCL501 may effectively reduce agitation in people with bipolar disorders or schizophrenia when used at home. This treatment, which is a sublingual film that dissolves under the tongue, was tested in a clinical trial where patients self-administered the drug during episodes of agitation. The results showed that BXCL501 significantly lowered agitation levels compared to a placebo, particularly in those experiencing severe agitation, and the benefits were consistent over time.

This discovery is important for anyone looking to manage mental health conditions effectively. For individuals with bipolar disorder or schizophrenia, reducing agitation can lead to improved daily functioning and overall well-being. The trial involved 200 patients who were able to take the medication at home, making it a potentially convenient option for those who may struggle with traditional treatment methods.

The evidence comes from a Phase 3 trial, which is a large-scale study designed to evaluate the safety and effectiveness of a treatment. While the results are promising, it’s important to note that BXCL501 has not yet been approved for this use by the U.S. Food and Drug Administration (FDA). The company plans to submit its findings for review, with a decision expected by November 2026. Until then, the treatment remains investigational, and more research will be needed to confirm its benefits and safety in broader populations.

Source: globenewswire.com